Study Name: Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Inmunodeficiency Virus (HIV) Coinfected
22 locations found
- 1220.19.0045 Boehringer Ingelheim Investigational Site
Location: Birmingham, Alabama
- 1220.19.0007 Boehringer Ingelheim Investigational Site
Location: Palm Springs, California
- 1220.19.0031 Boehringer Ingelheim Investigational Site
Location: San Francisco, California
- 1220.19.0005 Boehringer Ingelheim Investigational Site
Location: Washington, District of Columbia
- 1220.19.0086 Boehringer Ingelheim Investigational Site
Location: Fort Lauderdale, Florida
- 1220.19.0044 Boehringer Ingelheim Investigational Site
Location: Orlando, Florida
- 1220.19.0004 Boehringer Ingelheim Investigational Site
Location: Vero Beach, Florida
- 1220.19.0079 Boehringer Ingelheim Investigational Site
Location: Lutherville, Maryland
- 1220.19.0027 Boehringer Ingelheim Investigational Site
Location: Framingham, Massachusetts
- 1220.19.0008 Boehringer Ingelheim Investigational Site
Location: Camden, New Jersey
- 1220.19.0009 Boehringer Ingelheim Investigational Site
Location: Hillsborough, New Jersey
- 1220.19.0011 Boehringer Ingelheim Investigational Site
Location: Albany, New York
- 1220.19.0006 Boehringer Ingelheim Investigational Site
Location: New York, New York
- 1220.19.0014 Boehringer Ingelheim Investigational Site
Location: New York, New York
- 1220.19.0084 Boehringer Ingelheim Investigational Site
Location: New York, New York
- 1220.19.0021 Boehringer Ingelheim Investigational Site
Location: Winston-Salem, North Carolina
- 1220.19.0013 Boehringer Ingelheim Investigational Site
Location: Philadelphia, Pennsylvania
- 1220.19.0029 Boehringer Ingelheim Investigational Site
Location: Austin, Texas
- 1220.19.0012 Boehringer Ingelheim Investigational Site
Location: Dallas, Texas
- 1220.19.0060 Boehringer Ingelheim Investigational Site
Location: Fort Worth, Texas
- 1220.19.0016 Boehringer Ingelheim Investigational Site
Location: San Antonio, Texas
- 1220.19.0026 Boehringer Ingelheim Investigational Site
Location: Richmond, Virginia
|